MétaCan
Menu
Back to cohort
Record W4241025105 · doi:10.1002/cncr.20897

Author reply

2005· article· en· W4241025105 on OpenAlexaffabout
Rose Lai, Lauren E. Abrey

Bibliographic record

VenueCancer · 2005
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsMcMaster UniversityJuravinski Cancer Centre
Fundersnot available
KeywordsHazard ratioMedicineProportional hazards modelConfoundingSample size determinationObservational studyStatisticsConstant (computer programming)Confidence intervalEvent (particle physics)TrastuzumabInternal medicineOncologyCancerMathematicsBreast cancerComputer science

Abstract

fetched live from OpenAlex

We appreciate the thoughtful comments of Drs. Montemurro and Aglietta regarding our recently published article. We agree that it is important to compare time to the development of central nervous system metastases between those patients treated with trastuzumab and those who were not. However, the hazard rate (incidence rate in time-to-event analysis) of the two groups may not be constant over time; consequently, the derived crude hazards ratio may be inaccurate. We believe that a better method with which to estimate the hazards ratio is to use the Cox proportional hazards model. In addition to its ability to adjust for imbalances in baseline prognostic factors, the Cox model works well even when the hazards rates are not constant, provided that the ratio of the hazards rates is constant over time.1 The reason we did not perform a time-to-event analysis in our study was the limit of our sample size. Assuming an increase of the hazards ratio to 1.5 (a 50% increase), α = 0.05, β = 0.2, and a 3-year survival probability in the nontrastuzumab group of 45%,2 the minimum required sample size per group is 157 patients; we only had half of the number required in the trastuzumab-treated group. Moreover, unlike randomized trials, observational studies often require a larger sample size than the calculated minimum because of the presence of confounders. Because we were underpowered to perform such an analysis, we studied the development of CNS metastases as a binary variable that required fewer patients for the same power. One group of investigators compared the rate of acquiring brain metastases between patients receiving trastuzumab and those who were not and found no difference with regard to the time to the development of CNS disease.3 There is no question that time-to-event analysis is more informative, but as a first step, it still is reasonable to evaluate the overall association between trastuzumab therapy and subsequent disease recurrence in the CNS. It may be possible to examine time-to-brain metastases more accurately using large data sets available from relevant trials of the Cancer and Leukemia Group B (CALGB) or other cooperative groups. Rose Lai M.D.*, Lauren E. Abrey M.D. , * Department of Clinical Epidemiology and Biostatistics, Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.097
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.031
Threshold uncertainty score0.104

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.097
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0030.003
Scholarly communication0.0050.006
Open science0.0030.004
Research integrity0.0240.035
Insufficient payload (model declined to judge)0.0310.026

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.048
GPT teacher head0.416
Teacher spread0.368 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2005
Admission routes2
Has abstractyes

Explore more

Same venueCancerSame topicCancer Treatment and PharmacologyFrench-language works237,207